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Introduction: The introduction of tumor necrosis factor-alpha (TNF-α) antagonists has substantially improved
patient’s clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond
to anti-TNF-α treatment strategies. To identify valid predictors of TNF-α antagonist response in RA, serum proteome
profiles from responders (R) and non-responders (NR) to etanercept, a soluble recombinant TNF-α receptor/IgG Fc
fusion protein receptor, were compared in a prospective cohort study.
Methods: In this clinical study 50 RA patients with inadequate response to conventional DMARDs were included
and treated with etanercept. The primary efficacy endpoint was response according to the European League
against Rheumatism (EULAR) improvement criteria. Serum samples collected prior to initiation and after six months
of etanercept therapy were cleared of the most abundant major proteins by immunoaffinity chromatography. After
separation by two-dimensional differential gel electrophoresis (2D-DIGE) and identification by mass spectrometry
(MS) data were validated by Western blot analysis.
Results: After six months of etanercept treatment 62% (n = 31) of RA patients achieved response. Haptoglobin-α1
(Hp-α1) and -α2 (Hp-α2) and vitamin D-binding protein (VDBP) were found to be significantly upregulated in
responder sera (P ≤0.02) at study entry. In contrast, apolipoprotein C-III (ApoC-III) showed significantly higher levels
in non-responders (P = 0.0162). At study end ApoA-II, Hp-α1, Hp-α2 and VDBP were identified to be expressed at
significantly higher levels (P <0.05) in responder sera.
Conclusions: By application of clinical proteomics in immunodepleted sera we could identify and validate for the
first time Hp-α1, -α2, VDBP and ApoC-III as potential biomarkers for prediction of etanercept drug response in RA.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease of still unknown etiology with a prevalence of about
1% in the western population leading to progressive joint
deformities by cartilage destruction and bone erosion
[1]. For the pathogenesis of RA, proinflammatory cyto-
kines – especially tumor necrosis factor alpha (TNFα) –
were shown to play one of the most important roles in RA
pathogenesis by stimulation of matrix metalloproteinase
and proteolytic enzyme release from synoviocytes leading
to local cartilage degradation and demineralization of* Correspondence: sblasch@gwdg.de
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stated.bone in affected joints [2]. The course of the disease is
quite variable; however, about 10% of patients experience
progressive disease leading to marked joint deformities
and disability.
Conventional therapeutic approaches in RA are di-
rected at a nonspecific suppression of the inflammatory
process by so-called disease-modifying antirheumatic
drugs (DMARDs), such as the gold standard methotrex-
ate and leflunomide [3].
The introduction of biologic DMARD therapy targeting
proinflammatory cytokines, especially TNFα antagonists,
has substantially improved patient’s clinical outcome in
RA. Different TNFα inhibitors have so far been approved
for the treatment of RA. Efficacy and safety of the TNFα
antagonist etanercept [4], a soluble recombinant TNFαl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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onstrated in randomized and placebo-controlled studies.
Results of subsequent clinical trials suggest that concomi-
tant methotrexate therapy may enhance its efficacy [5].
However, despite these beneficial effects in RA patients’
treatment outcome, high therapeutic costs and adverse
drug reactions – such as severe infections, congestive
heart failure, and so forth [6] – limit a broad application
of TNFα antagonists in RA.
In addition, 20 to 40% of RA patients were previously
shown not to respond to anti-TNFα treatment strategies
[5,7]. Treatment failure may manifest as primary nonre-
sponse or secondary loss of response. Several factors
may account for the lack of efficacy, including different
pharmacokinetics of TNFα inhibitors, development of
anti-TNFα inhibitor antibodies, pharmacogenetics and
inadequate concomitant DMARD therapy. However, pre-
vious studies analyzing demographic factors [8], baseline
disease characteristics [9] or pharmacogenetic factors [10]
could not so far identify valid predictors of response to
anti-TNFα therapy in RA.
Recently, proteomic technologies – in particular, capil-
lary electrophoresis or liquid chromatography coupled
to electrospray ionization mass spectrometry (MS) as
well as surface enhanced laser desorption/ionization time-
of-flight MS together with bioinformatics tools – have
successfully been employed for identification of diagnostic
markers and therapeutic targets even in highly complex
body fluids [11,12] as well as for identification of drug-
modulated targets and response predictors [13]. It is thus
hypothesized that analysis of TNFα antagonist-modulated
alterations of the molecular circuitry by serum proteomic
profiling may help to identify response predictors for
TNFα antagonist therapy in RA.
In this prospective clinical cohort study, proteome pro-
files of serum samples were compared between responders
and nonresponders to etanercept treatment in RA patients
to identify potential predictors of drug response.
Methods
Patients and samples
A prospective clinical study was performed at the Uni-
versity Medical Center Goettingen, Germany. The study
was conducted in compliance with the principles laid
down in the latest version of the Declaration of Helsinki
and was finally approved by the local Institutional Re-
view Board at the University Medical Center Goettingen
(No. 14/12/2007).
All included patients (n = 50) met the criteria for RA
established by the American College of Rheumatology
[14] of more than 6 months’ disease duration. All RA
patients had active disease defined by three or more ten-
der joints, three or more swollen joints, physician and
patient assessment of pain of at least 40 mm or more ona 10 cm visual analogue scale and morning stiffness for >1
hour, with an elevated erythrocyte sedimentation rate (>28
mm/hour) or C-reactive protein (CRP >8 mg/l). Further-
more, all RA patients had inadequate response to standard
immunosuppressive therapy with methotrexate or lefluno-
mide. Exclusion criteria comprised all contraindications
against etanercept. After evaluation of all inclusion and
exclusion criteria at the screening visit (V1) and written
informed consent, RA patients were enrolled in the study
and assigned to receive etanercept treatment (50 mg
subcutaneously once per week) as TNFα antagonist
therapy at the baseline visit (V2). At each visit and at
trial week 4 (V3), week 8 (V4), week 12 (V5) and week
24 (V6), clinical disease activity (Disease Activity Score
in 28 joints (DAS28)) [15], physical function (Health
Assessment Questionnaire score) [16], vital signs and la-
boratory parameters including hematology, clinical
chemistry and immunologic parameters as well as CRP,
erythrocyte sedimentation rate, rheumatoid factor and
anti-cyclic citrullinated peptide antibodies were assessed
in the local laboratory. After 6 months of etanercept treat-
ment, response was assessed according to the European
League against Rheumatism improvement criteria [17]. A
major (good or moderate) response was defined as a de-
crease of DAS28 ≥ 1.2. Baseline characteristics of all RA
patients also including cardiovascular risk factors (arterial
hypertension, diabetes, tobacco use, hyperlipoproteinemia,
obesity, family history) are summarized in Table 1.
For clinical proteomics, sera (10 ml) were collected
from each RA patient prior to the initiation of TNFα
antagonist therapy (V1 and V2, pre-treatment samples)
and during the follow-up period at trial week 12 (V5)
and trial week 24 (V6) (post-treatment samples). Sam-
ples were stored at –80°C until analysis.
Serum depletion and protein precipitation
For clinical proteomics, 10 ml serum samples were taken
from RA patients at visits V1, V5 and V6. Sera were then
subjected to high-performance liquid chromatography-based
immunodepletion for high abundant proteins using Human-
14® immunoaffinity columns (Agilent, Boeblingen, Germany).
The depletion of high abundant proteins from sera was
carried out according to the manufacturer’s protocol. Subse-
quently, 6 M urea was added and the samples containing the
low abundant protein fractions were concentrated using
Vivaspin 4® (Sartorius Stedim, Goettingen, Germany) ultra-
filtration spin columns. Samples were mixed with ice-cold
precipitation solution (20% trichlororacetic acid in acetone)
at a ratio of 1:3. After centrifugation the protein pellets were
washed with ice-cold acetone and dried for 5 minutes.
The total protein concentration was estimated using the
Bradford method with bovine serum albumin (1 mg/ml) as
the standard [18] using the LAMBDA™ 25 spectrophoto-
meter (PerkinElmer, Waltham, Massachusetts, USA).
Table 1 Baseline characteristics of rheumatoid arthritis
patients at study entry
Patients Responder Nonresponder P value
Number of patients 31 19
Sex (male:female) 7:24 4:15 0.61
Mean (range) age
(years)
55.8 (41 to 75) 55.9 (40 to 71) 0.97
Cardiovascular risk
factors (≥1, % positive)
51.1 65.4 0.12
IgM-RF (% positive) 54.8 31.6 0.17
Anti-CCP (% positive) 64.5 31.6 0.15
Mean (standard
deviation) DAS28
4.82 (±1.19) 5.30 (±1.55) 0.22
Mean (range) CRP
(mg/l)
10.9 (2.0 to 114.5) 11.4 (2.0 to 80.7) 0.93
Mean (range) disease
duration (years)






Anti-CCP, anti-cyclic citrullinated peptide antibodies; CRP, C-reactive protein;
DAS28, Disease activity score in 28 joints at study visit V1; DMARD,
disease-modifying antirheumatic drug; RF, rheumatoid factor.
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For large-scale two-dimensional gel electrophoresis (2-DE),
immobilized pH gradient strips (11 cm, pI 3 to 10, pl 5 to
8) were passively rehydrated in 185 μl solution containing
150 μg protein in a rehydration buffer (8 M urea, 1% (w/v)
3-((3-cholamidopropyl)-dimethylammonio)-1-propane sul-
fonate (CHAPS), 1% dithiothreitol (DTT), 0.2% ampholytes,
and a trace of bromophenol blue) for 12 hours. The isoelec-
tric focusing step was performed on the PROTEAN® IEF
Cell (Bio-Rad, Hercules, California, USA). Temperature
controlled at 20°C, the voltage was set to 500 V for 1
hour, increased to 1,000 V for 1 hour and 2,000 V for 1
hour, and left at 8,000 V until a total of 50,000 V hours
was reached. Prior to SDS-PAGE, the immobilized pH
gradient strips were each reduced for 20 minutes at
room temperature in SDS equilibration buffer contain-
ing 6 M urea, 30% glycerol, 2% SDS 0.05 M Tris–HCl,
and 2% DTT on a rocking table. The strips were sub-
sequently alkylated in the same solution with 2.5%
iodacetamide substituted for DTT, and a trace of
bromophenol blue. For the SDS-PAGE, 12% BisTris
Criterion® precast gels (Bio-Rad) were used according to
the manufacturer’s instructions. The gels were run at 150
V for 10 minutes following by 200 V until the bromo-
phenol blue dye front had reached the bottom of the gel.Gel staining
For image analysis, 2-DE gels were fixed in a solution
containing 50% methanol and 12% acetic acid overnight
and stained with Flamingo® fluorescent gel stain (Bio-Rad)
for 5 hours. Gels were then scanned at 50 μm resolution
on a Fuji FLA-5100 scanner (Fuji Photo, Kanagawa,
Japan). Digitalized images were analyzed using Delta 2D
3.4 (Decodon, Greifswald, Germany). 2-DE gels were
post-stained with colloidal Coomassie® (Roti-Blue; Roth,
Karlsruhe, Germany) overnight to enable manual spot
picking for protein identification.
Protein CyDyes minimal labeling and two-dimensional
differential gel electrophoresis
To assure high data quality for two-dimensional differ-
ential gel electrophoresis (2D-DIGE), four biological rep-
licates consisting of sera from four patients per group
were collected. Serum depletion and protein precipita-
tion were performed as described above. The resulting
pellet was solubilized in labeling buffer (30 mM Tris–HCl
pH 8.5, 9.5 M urea, 2% CHAPS, 10 mM phenylmethylsul-
fonylfluoride) and centrifuged (5 minutes, 13,000 × g), and
the protein concentration of the supernatant was deter-
mined. Protein samples were labeled with CyDyes as de-
scribed previously [19]. For minimal labeling, 400 pmol
amine-reactive cyanine dyes Cy3 and Cy5 were added to
50 μg proteins from responders and nonresponders, re-
spectively. The labeling reaction was carried out at 4°C in
the dark for 30 minutes and the reaction was terminated
by addition of 10 nmol lysine at 4°C in the dark for 10
minutes. Equal volumes of 2× sample buffer (30 mM
Tris–HCl pH 8.5, 9.5 M urea, 2% CHAPS, 10 mM
phenylmethylsulfonylfluoride, 130 mM DTT and 2%
ampholytes 3-10) were added. To avoid dye-specific
protein labeling, every pair of protein samples from two
independent depleted serum samples from the same pa-
tient were processed in duplicate while swapping the
dyes. Thereby four replicate gels per patient serum were
obtained. Then 50 μg internal standard consisting of a mix-
ture of the two samples (responder and nonresponder)
under investigation were labeled with 400 pmol Cy2 and in-
cluded on all gels to facilitate gel matching. The three dif-
ferentially labeled fractions were pooled. Rehydration buffer
(8 M urea, 1% CHAPS, 13 mM DTTand 1% ampholytes 3-
10) was added to make up the volume to 185 μl prior to
isoelectric focusing. The 2-DE was performed as described
previously [19]. The CyDye-labeled protein gels were
scanned at 50 μm resolution on a Fuji FLA-5100 scanner
with excitation light at long pass 473 nm (Cy2), 575 nm
(Cy3) and 635 nm (Cy5). Fluorescent images were acquired
in 16-bit TIFF file format. Spot matching across gels
and normalization based on the internal standard was
performed with Delta2D 3.4 software. Statistical signifi-
cance of protein regulation as assessed by Student’s t test
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Coomassie®, differentially regulated proteins were
excised and processed for identification by MS.
In-gel digestion and mass spectrometry analysis
Manually excised gel plugs were subjected to an automated
platform for the identification of gel-separated proteins as
described recently [20]. An Ultraflex MALDI-TOF-TOF
mass spectrometer (Bruker Daltonik, Bremen, Germany)
was used to acquire both peptide mass fingerprinting and
fragment ion spectra, resulting in confident protein identi-
fications based on peptide mass and sequence information.
Database searches in the Swiss-Prot primary sequence
database restricted to the taxonomy Homo sapiens were
performed using the MASCOT Software 2.2 (Matrix
Science, London, UK). Carboxamidomethylation of Cys
residues was specified as fixed modification and oxidation
of Met residues as variable modifications. One trypsin-
missed cleavage was allowed. Mass tolerances were set to
100 ppm for peptide mass fingerprinting searches and to
100 ppm (precursor ions) and 0.7 Da (fragment ions) for
MS/MS ion searches. The minimal requirement for accept-
ing a protein as identified was at least one peptide sequence
match above identity threshold in addition to at least 20%
sequence coverage in the peptide mass fingerprinting.
Western blot analysis
Validation of the 2-DE data was carried out using western
blot (WB) analysis. To assure the reproducibility of the WB
analysis, at least three experimental replicates from each
patient’s serum were performed. Proteins (40 μg) were sepa-
rated by SDS-PAGE and transferred to Hybond® ECL nitro-
cellulose membrane (GE Healthcare, Freiburg, Germany).
Immunodetection was performed as described previously
[21]. Briefly, membranes were blocked in 5% milk for 2
hours at room temperature, followed by overnight incu-
bation at 4°C with diluted specific primary antibody includ-
ing polyclonal rabbit anti-human haptoglobin (Hp; 1:1,000),
rabbit anti-human apolipoprotein (Apo) C-III antibody
(Genway, San Diego, CA, USA), rabbit anti-human ApoA-II
antibody (Genway) or a rabbit anti-human vitamin
D-binding protein antibody (Abcam, Cambridge, UK).
After washing three times in Tris-buffered saline–Tween
buffer, nitrocellulose membranes were incubated with
the corresponding secondary antibody (Alexa Fluor 647
goat anti-mouse IgG antibody or Alexa Fluor 647 goat
anti-rabbit IgG, 1:2,000; Molecular Probes, Darmstadt,
Germany). Air-dried blot membranes were then
scanned at 50 μm resolution on a Fuji FLA-5100 scan-
ner with single laser-emitting excitation light at 635 nm.
Two-dimensional western blot
Proteins (150 μg) were separated by isoelectric focusing
and SDS-PAGE as described above and transferred toHybond® ECL nitrocellulose membrane. Immunodetec-
tion was performed as described above. Mouse mono-
clonal anti-vitamin D-binding protein (1:1,000; Abcam)
was used as primary antibody. Molecular Probes Alexa
Fluor 647 goat anti-mouse IgG antibody (1:2,000) was
used as secondary antibody.
Statistical analysis
All blots were quantified using ImageJ software (Open Ac-
cess Bioimaging Software, NIH, Bethesda, Maryland, USA).
The data were compiled with the software package Graph-
Pad Prism (version 4; La Jolla, California, USA). Statistical
differences between patient groups (responders and nonre-
sponders) were calculated by Student’s t test for paired and
unpaired samples. Results are presented as the mean ±
standard deviation of at least three independent experi-
ments. Differences were considered statistically significant
when P <0.05.
Results
Clinical outcome of etanercept treatment in RA patients
In this prospective cohort study, 50 RA patients with
high disease activity and inadequate response to stand-
ard DMARD therapy were included. After 6 months of
etanercept treatment (50 mg per week), 62% (n = 31) of
RA patients were judged as responders and 38% (n = 19)
as nonresponders to etanercept treatment. By comparison
of DAS28 scores between the baseline visit (V1) and end
of study (V6), these results were also reflected by a signifi-
cant reduction of DAS28 scores within the responder
group (P <0.0001) (Figure 1A). Furthermore, CRP and
interleukin (IL)-6 (data not shown) serum levels were sig-
nificantly reduced after 6 months of etanercept therapy in
responders (P = 0.036) (Figure 1B). No significant changes
were observed in the nonresponder group for DAS28,
CRP and IL-6 (data not shown) serum levels.
Comparative analysis of differentially expressed proteins
in sera of responders and nonresponders to etanercept
treatment in RA patients
To explore proteome differences between sera of re-
sponders and nonresponders, and thus to identify potential
predictors for etanercept treatment outcome, sera from
responders (n = 5) and nonresponders (n = 5) obtained at
study entry (V1) and at the end of study (V6) were sub-
jected to serum depletion using the Human-14® column
coupled to high-performance liquid chromatography to re-
move the 145 most abundant serum proteins. To assess the
reproducibility of the protein depletion, the same sample
was processed five times over the column and data repro-
ducibility was monitored using 2D-DIGE (see Additional
file 1). After optimization of the depletion protocol, serum
samples from different patients and visits were subjected to
serum depletion followed by protein concentration and 2D-
Figure 1 Clinical outcome of etanercept treatment in rheumatoid
arthritis patients. In this cohort study, patients with rheumatoid
arthritis (n = 50) and inadequate response to conventional
disease-modifying antirheumatic drugs were included. All patients
were subjected to etanercept (50 mg once per week) therapy and
evaluated according to European League against Rheumatism
improvement criteria after 6 months of therapy. (A) Disease Activity
Score in 28 joints (DAS28) scores compared between responders
(R) and nonresponders (NR) at baseline visit (V1) and at the end of
study (V6). (B) Furthermore, C-reactive protein (CRP) levels were
measured and compared at V1 and V6.
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excised and subjected to in-gel digestion and MS analyses.
A total of 180 spots were identified, which resulted in 55
nonredundant proteins (see Additional files 2, 3, 4 and 5).
Examination of single protein spots revealed significant
differences between the protein profiles of responders and
nonresponders. At baseline, five proteins were found to besignificantly upregulated in responders (Figure 2A; see
Additional file 6). These proteins were identified as vita-
min D-binding protein (VDBP), Hp-α1, Hp-α2, vitronec-
tin and ApoC-III. ApoA-II and ApoC-II levels were also
elevated, but only significant in a small proportion of the
samples. After 6 months of etanercept treatment (V6),
VDBP, Hp-α2, Hp-β and α1-antitrypsin were detected at
significantly higher levels in responders (Figure 2B).
Confirmation of 2D-DIGE results by western blot analysis
To confirm 2D-DIGE results, sera from responders (n = 5)
and nonresponders (n = 5) were subjected to fluorescent
WB analysis. As demonstrated in Figure 3, the data ob-
tained by 2D-DIGE for Hp-α1, Hp-α2 and ApoC-III could
be confirmed by WBs. In contrast, the higher levels of
ApoA-II in responders compared with nonresponders
seen in the 2D-DIGE analysis were found to hold true
only for three patients out of five, and in two patients
ApoA-II did not exhibit any significant differences in re-
sponders compared with nonresponders.
Validation of 2D-DIGE results in a larger cohort of RA
patients by western blot analysis
To validate results of 2D-DIGE analyses in responders and
nonresponders, one-dimensional WBs were performed for
Hp-α1, Hp-α2, ApoA-II and ApoC-III in a larger cohort of
RA patients (n = 31 responders and n = 19 nonresponders).
Results confirmed significant upregulation of Hp-α1 and
Hp-α2 in responder sera in comparison with nonresponder
sera prior to etanercept treatment initiation (V1) (P =
0.0231, P = 0.0185, respectively) as well as after 6 months
of therapy (V6) (P = 0.00445, P = 0.0038, respectively)
(Figure 4A,B). Interestingly, analysis of Hp phenotypes re-
vealed that the frequency of the phenotype Hp 2-2 was more
common in responders, and the phenotype Hp 2-1 was
found to be more common in nonresponders (Figure 4C).
In contrast to 2D-DIGE data, ApoC-III was found to
be significantly upregulated in nonresponder sera prior
to etanercept treatment (V1) (P = 0.0164) in comparison
with responders (Figure 4D). During the course of eta-
nercept treatment, results revealed no more significant
differences between responders and nonresponders.
For ApoA-II, an upregulation of protein expression
was detected in responders in comparison with nonre-
sponders (Figure 4E). However, these results were only
significant after 3 months (V5, P = 0.0114) and 6 months
(V6, P = 0.0228) of therapy.
Interestingly, in the case of VDBP the 2D-DIGE re-
vealed the presence of an extra form of the proteins in
responders compared with nonresponders, as evidenced
by the spot pattern on the two-dimensional gel. The
additional VDBP isoform seems to have a shift in iso-
electric point suggesting a posttranslational modification
such as changes in glycosylation pattern. To confirm
Figure 2 (See legend on next page.)
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Figure 2 Serum proteome profiles of responders and nonresponders to etanercept treatment in rheumatoid arthritis patients. Serum
samples of responders (n = 5) and nonresponders (n = 5) were pooled after immunodepletion and subjected to two-dimensional differential gel
electrophoresis analysis. Protein spot identification in serum proteome profiles of responders (R) and nonresponders (NR) was performed by
subsequent mass spectrometry. (A) Prior to initiation of etanercept treatment (V1), five proteins were found to be significantly upregulated in
responders including vitamin D-binding protein (VDBP), haptoglobin (Hp)-α1, Hp-α2, vitronectin and apolipoprotein C-III. (B) After 6 months of
therapy (V6), VDBP, Hp-α2, Hp-β and α1-antitrypsin were found at significantly elevated levels in responder sera. MW, molecular weight.
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demonstrated clearly that VDBP was present in four dif-
ferent forms in responder sera, but in only three iso-
forms in nonresponder sera (Figure 5).
Discussion
In this study, identification of novel biomarkers as valid
predictors of etanercept drug response in RA was suc-
cessfully achieved by serum proteomic profiling in re-
sponders and nonresponders.
In RA, the introduction of TNFα inhibitors as bio-
logical agents has substantially improved the patient’s
long-term outcome. Low disease activity or even disease
remission now represents the ultimate therapeutic goal
by adoption of a treat-to-target strategy to achieve tight
disease control. However, several large clinical studies
have demonstrated that up to 20 to 40% of RA patients
do not respond to anti-TNFα biologicals. The prediction
of individual response biological treatment has thus be-
come a major clinical challenge. The need for a person-
alized therapeutic strategy in RA is stressed by the fact
that early effective treatment has an enormous impactFigure 3 Western blot analysis of responder and nonresponder sera.
for haptoglobin (Hp)-α1, Hp-α2, apolipoprotein (Apo)C-III and ApoA-II were ca
(n = 5) were subjected to western blot analysis with antibodies against the m
upregulation of Hp-α1 and Hp-α2 band intensities in comparison with no
etanercept treatment (V6). In contrast, the ApoC-III upregulation in respon
found to be significantly upregulated in responders only after 3 months (Von patient’s overall prognosis for disease outcome. Fur-
thermore, TNFα inhibitors may cause serious side effects
and are cost-intensive in comparison with conventional
DMARD therapies.
Several previous studies have analyzed clinical, labora-
tory and genetic factors as potential predictors of TNFα
antagonist drug response: large cohort studies have re-
vealed that older age, low functional status and concomi-
tant prednisolone [22] as well as smoking, glucocorticoid
use and worse physician assessment of disease activity at
baseline [11,23] are negative predictors of clinical response
to TNFα antagonists, whereas treatment with concomi-
tant DMARDs and low disability were found to be associ-
ated with good response [24]. Heterogeneous results have
been reported for the presence and titers of anti-cyclic
citrullinated peptide antibodies [25,26]. Novel biomarkers
such as IL-6 [25], IL-21 [27] and CD11c [28] as well as tis-
sue biomarkers [29] have only been studied in small co-
horts or experimental settings. Recent progress in defining
genetic factors for response by analysis of single nucleo-
tide polymorphisms [30-32] and genome-wide association
studies [33] yielded promising results. Furthermore, serumTo validate results of serum proteome profiling, western blot analyses
rried out. Serum samples from responders (n = 5) and nonresponders
entioned proteins. At baseline (V1), responder sera revealed a significant
nresponders. These results were also detected after 6 months of
ders could only be confirmed at baseline (V1). ApoA-II levels were
5) and 6 months (V6) of therapy in comparison with nonresponders.
Figure 4 (See legend on next page.)
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Figure 4 Validation of results in a larger cohort of rheumatoid arthritis patients by western blot analysis. To validate results of two-dimensional
differential gel electrophoresis analyses, one-dimensional western blots were performed for haptoglobin (Hp)-α1, Hp-α2, apolipoprotein
(Apo)A-II and ApoC-III in a larger cohort of rheumatoid arthritis patients (n = 31 responders and n = 19 nonresponders). (A, B) The statistical
analysis of the western blot data confirmed the significant upregulation of Hp-α1 and Hp-α2 in responder (R) sera in comparison with
nonresponder (NR) sera prior to etanercept treatment initiation (V1) (P = 0.0231, P = 0.0185, respectively) as well as after 6 months of therapy
(V6) (P = 0.00445, P = 0.0038, respectively). (C) Interestingly, analysis of Hp phenotypes Hp 2-1, Hp 2-2 and Hp 1-1 revealed that the frequency of
the phenotype Hp 2-2 was more common in R in comparison with NR, whereas the phenotype Hp 2-1 was found to be more common in NR.
(D) In contrast to proteomics data, the western blot analysis in a larger patient cohort showed an upregulation of ApoC-III in NR sera prior to
etanercept treatment (V1) in comparison with responders. (E) During the course of etanercept treatment, no more significant differences
between R and NR could be detected. Upregulation of ApoA-II expression was detected in R in comparison with NR only after 3 months (V5)
and 6 months (V6) of therapy.
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in RA patients receiving biological therapies and detected
differential expression of several small proteins including
apolipoproteins [34-37]. However, none of these studies
could clearly identify valid predictors for TNF-alpha an-
tagonist drug response. Thus, none of these models has so
far been translated into clinical application.
In this study we analyzed potential predictors of eta-
nercept drug response by a clinical proteomics approach
in sera of responders and nonresponders. Results revealed
differential regulation of small serum protein expression
between responders and nonresponders prior to the initi-
ation of etanercept treatment and after 3 and 6 months of
therapy. Significant upregulation of protein expression
was detected in pretreatment samples of responders for
Hp-α1, Hp-α2 and VDBP. In contrast, ApoC-III levelsFigure 5 Two-dimensional western blot analysis of vitamin D-binding
of vitamin D-binding protein (VDBP) expression, two-dimensional western
detected at V1 in responders (R) and nonresponders (NR). 2D-WB revealed
posttranslational modification such as changes in glycosylation pattern. 2Dwere found to be significantly upregulated in nonre-
sponders prior to initiation of etanercept treatment. Fur-
thermore, significant changes of these proteins were also
detected during follow-up after 6 months of therapy be-
tween responders and nonresponders. By analyzing the
impact of treatment duration (0, 3 and 6 months) on the
protein level within the same patient group, no significant
differences could be detected between V1, V5 and V6. Dif-
ferences were only significant between responders and
nonresponders. This finding suggests that there is no
clear correlation between the treatment duration and
the serum protein levels within the same group.
Haptoglobin is a polypeptide structurally consisting of
two α chains (α1 or α2) and two β chains. Hp represents
an acute phase protein that is induced via proinflamma-
tory cytokines such as IL-6, IL-1 or TNFα. According toprotein isoforms in responders and nonresponders. For analysis
blot (2D-WB) analysis was performed. Different isoforms of VDBP were
an additional VDBP isoform in R compared with NR, suggesting a
-DIGE, two-dimensional differential gel electrophoresis.
Blaschke et al. Arthritis Research & Therapy  (2015) 17:45 Page 10 of 12the presence of the α1 or α2 chains, three different phe-
notypes (Hp 1-1, Hp 2-1, Hp 2-2) could be distinguished
[38]. Previous studies have revealed that Hp 2-2 pheno-
types are genetically associated with inflammatory and
autoimmune diseases [39]. Functionally, Hp binds free
hemoglobin and thus represents a marker for hemolysis.
Furthermore, Hp was shown previously to exert add-
itional anti-oxidative, anti-inflammatory and immuno-
regulatory effects: owing to the structural similarity with
7S immunoglobulin, Hpα may suppress cellular immune
responses. In addition, Hp was shown to restore homeo-
stasis after inflammatory processes [40] and to bind on
activated macrophages, thus leading to the inhibition of
TNFα production [41]. In this study, responders were
characterized by a significant upregulation of Hpα1 and
Hpα2 production prior to the initiation and after 6
months of etanercept therapy in RA. These findings may
support the hypothesis that Hpα chains may support anti-
inflammatory effects of etanercept in RA. Responders may
profit from upregulated Hpα chain expression in RA prior
to and during the course of etanercept therapy. Further-
more, the Hp 2-2 phenotypes were found to be more
common in responders, whereas Hp 2-1 were mainly de-
tected in the nonresponder group. Upregulation of Hpα1
and Hpα2 expression and Hp phenotype thus may repre-
sent valid markers for prediction of response to etanercept
therapy in RA.
ApoC-III is a small protein containing 79 amino acids
that resides on the surface of lipoproteins. Physiological
functions of ApoC-III include the inhibition of lipopro-
tein lipase and hepatic lipase. ApoC-III thus represents a
major regulator of lipolysis. In consequence, elevated
ApoC-III levels have been detected in patients with
hypertriglyceridemia [42]. Furthermore, genetic variation
studies have revealed that distinct ApoC-III haplotypes
predispose for a higher risk of coronary heart disease
and diabetes mellitus. In addition to these effects on lip-
olysis, there is emerging scientific evidence that ApoC-
III exerts proinflammatory effects on both monocytes
and endothelial cells during the pathogenesis of athero-
sclerosis: ApoC-III was previously shown to induce the
expression of intercellular adhesion molecule-1 and
vascular adhesion molecule-1 in endothelial cells [43].
Furthermore, ApoC-III was found to augment arterial
inflammation by stimulating the adherence of peripheral
monocytes to endothelial cells [44] and to initiate the
transcription of proinflammatory cytokines via activation
of nuclear factor-κB in monocytes [45]. In this study,
significantly elevated ApoC-III serum levels were de-
tected in the nonresponder group in comparison with
responders prior to initiation of etanercept therapy. In
correlation with previous findings concerning cardiovas-
cular comorbidity, nonresponders in our study popula-
tion were characterized by a higher (but nonsignificant)incidence of concomitant cardiovascular risk factors
(Table 1). Upregulation of ApoC-III in nonresponders
may counteract therapeutic effects of etanercept by an-
tagonism of TNFα blockade and thus may be respon-
sible for treatment failure in this RA patient group. This
hypothesis may be supported by the finding that ApoC-
III levels positively correlate with IL-6 serum levels at
study entry (data not shown). This correlation was sta-
tistically not significant, however, perhaps due to the
limited number of samples analyzed in this study.
VDBP is a multifunctional α2-globulin (50 to 52 kDa).
Its main functional role is the binding and transport of
vitamin D metabolites to effector cells. Owing to the fact
that vitamin D3 is essential for bone metabolism and ex-
erts immunomodulatory effects via inhibition of T-helper
cell type 1 T-cell responses and proinflammatory cytokine
action (IL-1, IL-6), VDBP is thought to support positive ef-
fects on both bone metabolism and immune system by in-
duction of anti-inflammatory pathways [46]. Furthermore,
VDBP is essential for G-actin binding to inhibit uncon-
trolled intravascular G-actin polymerization after cellular
tissue damage, and thus to inhibit microembolism and
organ dysfunction after cellular necrosis.
In responders, VDBP was detected at significantly ele-
vated levels in this study. It is thus hypothesized that in
responders VDBP and etanercept may exert synergistic
effects on bone metabolism and immune function in
RA. In this respect, responders characterized by elevated
VDBP levels may profit from a higher vitamin D3 avail-
ability and G-actin binding capacity after cellular necro-
sis in comparison with nonresponders. This hypothesis
may be supported by the finding of a negative correl-
ation between VDBP and IL-6 serum levels at study
entry (data not shown); however, the correlation analysis
was again statistically not significant. The small number
of serum samples analyzed and the large number of fac-
tors (cytokines, hormones and concomitant diseases)
known to influence IL-6 serum levels may account for
this finding.
Interestingly, a posttranslational modification of VDBP
was detected in responders by two-dimensional WB as
compared with nonresponders. The pattern of this
modification suggests changes in glycosylation status for
responders. Previous studies have demonstrated that
glycosylation of VDBP leads to the production of macro-
phage activating factor via T-cell and B-cell associated
enzymes [47]. Macrophage activating factor production
was shown to induce proinflammatory, anti-angiogenic,
anti-tumorous and anti-proliferative effects [48]. It is thus
hypothesized that, in nonresponders characterized by gly-
cosylated isoforms of VDBP, treatment failure of etaner-
cept may be due to the overproduction of macrophage
activating factor. However, this hypothesis still has to be
analyzed and validated in future experimental studies.
Blaschke et al. Arthritis Research & Therapy  (2015) 17:45 Page 11 of 12In this study, several biomarkers for response to eta-
nercept treatment could be identified by application of a
clinical proteomics approach. However, a small sample
size represents a limitation of the study. Furthermore,
limitations of the clinical proteomics approach in identi-
fying biomarkers are demonstrated and underline the
necessity of proteomics data validation.Conclusions
By application of a clinical proteomics approach, our study
demonstrates that small serum proteins such as Hp-α1,
Hp-α2, VDBP and ApoC-III may serve as valid predictors
for etanercept drug response in RA. Further studies in lar-
ger and independent cohorts are required to confirm the
study results and to develop the best model with the
greatest predictive accuracy for treatment response to eta-
nercept in RA.Additional files
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